Overview

Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma

Status:
Completed
Trial end date:
2015-11-10
Target enrollment:
Participant gender:
Summary
Topotecan is a FDA-approved drug when given by intravenous injection, but it is not effective against brain tumors when given intravenously. The Cleveland Multiport Catheter is a new, investigational device that will be used to deliver topotecan directly into participants' brain tumors. One purpose of this study is to determine whether the Cleveland Multiport Catheter can be used effectively and safely to deliver topotecan directly into brain tumors. This study will also evaluate different doses of topotecan that can be delivered to a participant's brain tumor with use of the Cleveland Multiport Catheter, and it will also examine how their tumor responds to treatment with topotecan.
Phase:
Early Phase 1
Details
Lead Sponsor:
Michael Vogelbaum, MD, PhD
Collaborator:
Infuseon Therapeutics, Inc.
Treatments:
Topotecan